Search
for

    Glossary Winlevi

    Winlevi, or clascoterone, is a topical medication approved for the treatment of acne and is being investigated for its potential use in addressing androgenetic alopecia, a common form of hair loss. It functions as an androgen receptor inhibitor, which means it can block the effects of androgens like dihydrotestosterone (DHT) that contribute to hair follicle miniaturization. Its relevance in hair biology lies in its ability to target the hormonal pathways involved in hair loss, offering a novel approach to treatment without the systemic side effects associated with oral medications. Key distinguishing characteristics include its topical application and its mechanism of action that specifically addresses androgen-related hair loss.

    Sort by

    Research 19

    1. Clascoterone: First Approval Drugs · 2020 · 27 citations
    2. Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist Expert opinion on pharmacotherapy · 2021 · 9 citations
    3. Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream Clinical Cosmetic and Investigational Dermatology · 2022 · 4 citations
    4. Journal of Pigmentary Disorders Journal of Pigmentary Disorders · 2019 · 3 citations
    5. Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review Pharmaceuticals · 2026
    6. BRIDGING THE GAP IN ACNE MANAGEMENT: A NARRATIVE REVIEW OF CURRENT THERAPIES AND THE EMERGENCE OF CLASCOTERONE International Journal of Innovative Technologies in Social Science · 2026
    7. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments American Journal of Clinical Dermatology · 2026
    8. TRADITIONAL AND ALTERNATIVE METHODS OF ACNE TREATMENT Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì · 2024
    9. Editorial Note on Next-Generation Therapies and Advance Acne Treatment 2021
    10. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris American Journal of Clinical Dermatology · 2019 · 7 citations
    11. Industry update: the latest developments in the field of therapeutic delivery, July 2018 Therapeutic Delivery · 2018 · 1 citations
    12. Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique HAL (Le Centre pour la Communication Scientifique Directe) · 2025
    13. Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience Canadian dermatology today. · 2025
    14. Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies International Journal of Molecular Sciences · 2024 · 68 citations
    15. Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review American Journal of Clinical Dermatology · 2025
    16. Recent Advances in Drug Development for Hair Loss International Journal of Molecular Sciences · 2025
    17. Managing Common Dermatologic Needs in Transgender and Gender-Diverse Adolescents Current Pediatrics Reports · 2025
    18. Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists Dermatology and Therapy · 2025
    19. Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience Clinical Cosmetic and Investigational Dermatology · 2025